Literature DB >> 17011519

Fetuin-null mice are protected against obesity and insulin resistance associated with aging.

Suresh T Mathews1, Sanjay Rakhade, Xiaohua Zhou, Graham C Parker, Donald V Coscina, George Grunberger.   

Abstract

alpha2-HS glycoprotein (AHSG), also known as fetuin-A, inhibits insulin receptor autophosphorylation and tyrosine kinase activity in vitro and in vivo. Earlier we have shown that fetuin-null (KO) mice demonstrate improved insulin sensitivity and resistance to diet-induced obesity. Since aging is associated with insulin resistance and impaired glucose handling, we tested the hypothesis that fetuin-null (KO) mice are resilient to changes in insulin sensitivity associated with aging. Aged (80-week-old) fetuin-null mice were leaner and demonstrated significantly lower body weights compared to age- and sex-matched wild-type (WT) littermates. Leanness in aged fetuin KO mice was accompanied by a significant increase in dark-onset energy expenditure, without marked alteration of respiratory quotient. In comparison to WT mice, fetuin KO mice demonstrated a lower fasting insulin resistance index, and significantly lower blood glucose and insulin levels, following a 4h fast. Interestingly, despite significantly decreased insulin levels during a glucose tolerance test, aged fetuin-null mice demonstrated a similar glucose excursion as WT mice, indicative of improved insulin sensitivity. Analysis of aldehyde-fuchsin stained pancreas from aged fetuin KO mice indicated no difference in islet beta-cell size or number. An insulin tolerance test confirmed the increased insulin sensitivity of aged fetuin KO mice. Further, compared to WT mice, aged fetuin-null mice demonstrated increased skeletal muscle and liver IR autophosphorylation and TK activity. Taken together, this study suggests that the absence of fetuin may contribute to the improvement of insulin sensitivity associated with aging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011519     DOI: 10.1016/j.bbrc.2006.09.071

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  39 in total

1.  A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging.

Authors:  Fabian Sanchis-Gomar; Helios Pareja-Galeano; Alejandro Santos-Lozano; Nuria Garatachea; Carmen Fiuza-Luces; Letizia Venturini; Giovanni Ricevuti; Alejandro Lucia; Enzo Emanuele
Journal:  Age (Dordr)       Date:  2015-04-25

2.  Role of the cytoskeleton in muscle transcriptional responses to altered use.

Authors:  Gretchen A Meyer; Simon Schenk; Richard L Lieber
Journal:  Physiol Genomics       Date:  2013-02-26       Impact factor: 3.107

3.  Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity.

Authors:  Steven K Malin; Juan Pablo del Rincon; Hazel Huang; John P Kirwan
Journal:  Med Sci Sports Exerc       Date:  2014-11       Impact factor: 5.411

Review 4.  Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes.

Authors:  Josiah Ochieng; Gladys Nangami; Amos Sakwe; Cierra Moye; Joel Alvarez; Diva Whalen; Portia Thomas; Philip Lammers
Journal:  Int J Mol Sci       Date:  2018-07-29       Impact factor: 5.923

5.  Specifics of fetuin-A levels in distinct types of chronic heart failure.

Authors:  Michael Lichtenauer; Bernhard Wernly; Vera Paar; Ilonka Rohm; Christian Jung; Atilla Yilmaz; Uta C Hoppe; Paul Christian Schulze; Daniel Kretzschmar; Rudin Pistulli
Journal:  J Clin Lab Anal       Date:  2017-02-18       Impact factor: 2.352

6.  Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Kenneth J Mukamal; David E St-Jules; Matthew J Budoff; Ronit Katz; Michael H Criqui; Matthew A Allison; Ian H de Boer; David S Siscovick; Joachim H Ix; Majken K Jensen
Journal:  Am J Epidemiol       Date:  2016-11-17       Impact factor: 4.897

Review 7.  Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.

Authors:  Sazan Rasul; Ludwig Wagner; Alexandra Kautzky-Willer
Journal:  Endocrine       Date:  2012-07-21       Impact factor: 3.633

8.  Circulating Fetuin-A and Risk of Type 2 Diabetes: A Mendelian Randomization Analysis.

Authors:  Janine Kröger; Karina Meidtner; Norbert Stefan; Marcela Guevara; Nicola D Kerrison; Eva Ardanaz; Dagfinn Aune; Heiner Boeing; Miren Dorronsoro; Courtney Dow; Guy Fagherazzi; Paul W Franks; Heinz Freisling; Marc J Gunter; José María Huerta; Rudolf Kaaks; Timothy J Key; Kay Tee Khaw; Vittorio Krogh; Tilman Kühn; Francesca Romana Mancini; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Elena Salamanca-Fernández; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Konstantinos K Tsilidis; Rosario Tumino; Yvonne T van der Schouw; Nita G Forouhi; Stephen J Sharp; Claudia Langenberg; Elio Riboli; Matthias B Schulze; Nicholas J Wareham
Journal:  Diabetes       Date:  2018-03-09       Impact factor: 9.461

9.  The association of uncarboxylated matrix Gla protein with mitral annular calcification differs by diabetes status: The Heart and Soul study.

Authors:  Benjamin D Parker; Leon J Schurgers; Cees Vermeer; Nelson B Schiller; Mary A Whooley; Joachim H Ix
Journal:  Atherosclerosis       Date:  2009-11-22       Impact factor: 5.162

10.  Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance.

Authors:  Durba Pal; Suman Dasgupta; Rakesh Kundu; Sudipta Maitra; Gobardhan Das; Satinath Mukhopadhyay; Sukanta Ray; Subeer S Majumdar; Samir Bhattacharya
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.